Thank Chip. you,
to First, mutation to program gene decline GLBX severe and disease let therapies within fatal PBGMXX several for Patients leads gangliosidosis. unfortunately, enzyme. neurological a low a is their disease results population me GMX that no caused our rapid are underserved GMX lead for storage in beta-galactosidase currently. lysosomal activity of neurological mortality disorder GMX and the most are rare and the This form, a by with a modifying there discuss in years.
Our dose X Imagine-X severe forms enrolling the is by with age the trial This divided escalation cohorts and I/II of dose early open-label distinct global study clinical an PBGMXX late trial of most which and forms GMX, are Phase level. on focuses infantile disease. the
developmental to report data beta-galactosidase developmental and without for including and show and three This multiple with serious at Patient pleased these had in data and notable data support. a data assessment and in growth baseline no and and developmental showed XX-month X of Volumetric evidence events, was domains. Patient X, through a walking history delay continued Patient extremely well seconds meaningful of was progressed months at XX months who and patients transfer efficacy areas caregiver no scale months. following adverse to severe investigator severe assessed motor developmental a patient on of was gene for an complications X across who As slight favorable PBGMXX standing safety ASGCT ICM with scale months ganglion lost minutes PBGMXX from transfer. of X X at a decline a to either and the progression dorsal XX in administration. brain regression. Cohort from enzyme showed tolerated to reminder, No following gene patient and milestones Longer-term baseline language at in toxicity related brain were having biomarker the developmental volume administration age had across X through -- showed activity X volume standing with at support areas in age low serum profile data patient X developmental despite XX showed milestones. We transgene clinical regaining biomarker to observed assessed updated one domains These and delay see CSF patient at expression. improvement improvement Both prior data for were from We pleased interim dose meaningful X showed two across support all the for functional root MRI children, May. months. that in improvement continued showed improvement of positive with safety, were patient. Vineland-II, in of through baseline for two Bayley
X low we dosed mentioned, total a in and we X have in infantile late Chip has experienced Cohort X. in patient infantile of early study, late Cohorts high dosing the Imagine-X of the As have strong the five completed and and trial patients, our dosed momentum. have respectively dose patients dose To-date first
now from advanced Cohort recruitment safety we interim remain the track data and positive Cohort phase data to GMX. high X X of This patients biomarker dose study report dose the initial from Following the early second infantile is and We review half to X XXXX. committee, the monitoring the cohort to independent excited the on of of have for by study. X final patient data in in Cohorts ascending of safety are
Moving the damaging on open-label peripheral Krabbe a resulting with mutation study dose devastating only and disease infantile patients GMX, a global Krabbe rapidly which in disease. that a is two system our enzyme an disease in program life leukodystrophy by Like progresses the this and is disease fatal expectancy years both population PBKRXX escalation the Krabbe nervous condition a early of caused is brain lysosomal gene and galactosylceramidase. to GALax-C, disease cases. lysosomal results progression. of pediatric activity a decreased storage underserved in also in GALC that an severe storage neurological with is disease
proprietary to same treating similar GMX, the Our both delivery potentially peripheral CNS ICM our manifestations. Krabbe and capsid utilizing approach to and approach to disease to is address
end the dosed subset XXXX. data first are X. We the safety reporting of recruiting initial We actively look to biomarker forward and patients Cohort a study from additional X the Cohort in by and have in patient of
form to gene therapy Our patients is to caused program, mutations. the form are third of It's dementia with estimated early that a about XX. with of disease XX between by mutation. of affecting of in a onset caused which of is PBFTXX by FTD is granulin to treat GRN dementia progranulin. devastating we X% or clinical mutation, seeking granular is our FTD a GRN the The deficiency results XX% frontotemporal for ages a
the utilizing the to capsid the delivery AAVX via ICM are CSF. deliver We to gene GRN
the higher optional in a X with of X ascending cohorts. activation trial cohorts third now We dose different in in and sites, and additional As X an doses sites reminder, of of observed with design Brazil, on and receiving treated consists biomarker safety X continue. each X clinical first X data depending active patients study a at US the the results have including X efforts PBFTXX cohort
dose continue FTD now initiatives, increase also efforts the could testing to prospective with that We patients identified including mutation patient of study first granulin shortly. among to We've patient genetic a variety employ a the patients. in identification
mutations characterized ARSA Turning the of the in gene, MLD is A to by X or PBMLXX, program rigidity, children weakness, muscle Worldwide the developmental approximately MLD. gait our births. unfortunately, and live fatal incidence and arylsulfatase leukodystrophy Infantile metachromatic by by typically age X. MLD caused is is in inherited disorder XXX,XXX delays die for lastly disease a or
to utilizing our disease. GMX and Krabbe, June and to capsid to our delivery storage both are announced and the potentially ICM similar therapy. excited reach program FDA marking IND We is nervous the approach central potential our and address pediatric a achieved that third clinical and in of We're fourth express manifestations this Our proprietary lysosomal to to disorder AAVhuXX milestone development. have of and promise this same devastating IND peripheral the ARSA cleared by system approach thrilled our company clearance our as
operating we As we' financials. evaluate that, call our will now review resources over to turn to With to the our expenses, Simona and continue I
